Article Text
Electronic pages
Correspondence response
HCV-associated cryoglobulinemic vasculitis: triple/dual antiviral treatment and/or rituximab? Reply to the comment by Ignatova et al
Statistics from Altmetric.com
We thank Ignatova and colleagues1 for their interest in our work regarding peginterferonα-ribavirin/protease inhibitor combination in hepatitis C virus-associated mixed cryoglobulinaemia vasculitis (HCV-MC),2 and in bringing new elements up for discussion.
Ignatova et al emphasise the priority to clear the virus in HCV-MC. They reported 65 patients with HCV-associated MC vasculitis who were treated with conventional immunosuppresive drugs only (n=30), monotherapy with interferon-alfa (n=9) or rituximab (n=8) or peginterferon-alfa/ribavirin±rituximab …
Footnotes
-
Competing interests None.
-
Provenance and peer review Commissioned; internally peer reviewed.